Chronic Myelomonocytic Leukemia clinical trials at UCLA
2 in progress, 1 open to eligible people
APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
open to eligible people ages 18-99
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML. The study consists of dose escalation (Part I) and dose expansion phase (Part II)
Los Angeles, California and other locations
Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Sorry, in progress, not accepting new patients
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy
Los Angeles, California and other locations
Our lead scientists for Chronic Myelomonocytic Leukemia research studies include Caspian Oliai, MD.
Last updated: